110 related articles for article (PubMed ID: 19120399)
21. Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group.
Califano R; Griffiths R; Lorigan P; Ashcroft L; Taylor P; Burt P; Lee L; Chittalia A; Harris M; Faivre-Finn C; Thatcher N; Blackhall F
Lung Cancer; 2011 Sep; 73(3):338-44. PubMed ID: 21296449
[TBL] [Abstract][Full Text] [Related]
22. A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancer.
Jones S; Thompson D; Barton J; Patton J; Shipley D; Greco FA; Spigel D; Infante J; Burris HA
Clin Lung Cancer; 2008 May; 9(3):154-9. PubMed ID: 18621625
[TBL] [Abstract][Full Text] [Related]
23. A rare manifestation of nail changes with docetaxel therapy.
Halvorson CR; Erickson CL; Gaspari AA
Skinmed; 2010; 8(3):179-80. PubMed ID: 21137627
[TBL] [Abstract][Full Text] [Related]
24. Improvement in docetaxel-induced nail changes associated with cyclooxygenase-2 inhibitor treatment.
Nakamura S; Kajita S; Takagi A; Hashimoto Y; Ishida-Yamamoto A; Takahashi H; Iizuka H
Clin Exp Dermatol; 2009 Oct; 34(7):e320-1. PubMed ID: 19456779
[No Abstract] [Full Text] [Related]
25. Severe nail changes due to Docetaxel treatment.
Rafi L; Friedrich M; Tilgen W; Reichrath J
Eur J Dermatol; 2003; 13(6):610-1. PubMed ID: 14721789
[TBL] [Abstract][Full Text] [Related]
26. Comparison of pharmacokinetics and pharmacodynamics of docetaxel and Cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients?
Minami H; Ohe Y; Niho S; Goto K; Ohmatsu H; Kubota K; Kakinuma R; Nishiwaki Y; Nokihara H; Sekine I; Saijo N; Hanada K; Ogata H
J Clin Oncol; 2004 Jul; 22(14):2901-8. PubMed ID: 15254059
[TBL] [Abstract][Full Text] [Related]
27. Safety and long-term efficacy of partial matricectomy and phenolization for the treatment of pyogenic granuloma-like lesions induced by epidermal growth factor receptor inhibitors.
Mariano M; Lorenzi S; De Padova MP; Fabbrocini G; Cameli N
G Ital Dermatol Venereol; 2020 Aug; 155(4):517-518. PubMed ID: 30249089
[No Abstract] [Full Text] [Related]
28. Docetaxel vs. vinorelbine in elderly patients with advanced non--small-cell lung cancer: a hellenic oncology research group randomized phase III study.
Karampeazis A; Vamvakas L; Agelidou A; Kentepozidis N; Chainis K; Chandrinos V; Vardakis N; Pallis AG; Christophyllakis C; Georgoulias V
Clin Lung Cancer; 2011 May; 12(3):155-60. PubMed ID: 21663857
[TBL] [Abstract][Full Text] [Related]
29. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.
Kotsakis A; Agelaki S; Vardakis N; Stathopoulos G; Vamvakas L; Kalykaki A; Kentepozidis N; Kontopodis E; Sfakiotaki G; Mavroudis D; Georgoulias V
Cancer Chemother Pharmacol; 2011 Aug; 68(2):415-22. PubMed ID: 21069335
[TBL] [Abstract][Full Text] [Related]
30. Cabozantinib-induced hand-foot skin reaction with subungual splinter hemorrhages and hypertension: a possible association with inhibition of the vascular endothelial growth factor signaling pathway.
Cho YT; Chan CC
Eur J Dermatol; 2013 Apr; 23(2):274-5. PubMed ID: 23518371
[No Abstract] [Full Text] [Related]
31. Fatal ischemic bowel necrosis possibly due to docetaxel and cisplatin in a patient with non-small cell lung cancer.
Kanat O; Evrensel T; Kurt E; Keskin K; Akcali U; Manavoglu O
Lung Cancer; 2007 Apr; 56(1):143-4. PubMed ID: 17291625
[TBL] [Abstract][Full Text] [Related]
32. Docetaxel-induced photo-recall phenomenon.
Droitcourt C; Le Hô H; Adamski H; Le Gall F; Dupuy A
Photodermatol Photoimmunol Photomed; 2012 Aug; 28(4):222-3. PubMed ID: 23017178
[TBL] [Abstract][Full Text] [Related]
33. Interstitial lung disease associated with docetaxel in patients with advanced non-small cell lung cancer.
Tamiya A; Naito T; Miura S; Morii S; Tsuya A; Nakamura Y; Kaira K; Murakami H; Takahashi T; Yamamoto N; Endo M
Anticancer Res; 2012 Mar; 32(3):1103-6. PubMed ID: 22399640
[TBL] [Abstract][Full Text] [Related]
34. Brief report: retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy.
Ng R; Loreto M; Lee R; Leighl NB
Lung Cancer; 2008 Aug; 61(2):262-5. PubMed ID: 18358559
[TBL] [Abstract][Full Text] [Related]
35. Taxane-induced nail changes: Predictors and efficacy of the use of frozen gloves and socks in the prevention of nail toxicity.
Can G; Aydiner A; Cavdar I
Eur J Oncol Nurs; 2012 Jul; 16(3):270-5. PubMed ID: 21784705
[TBL] [Abstract][Full Text] [Related]
36. Docetaxel in advanced non-small cell lung cancer.
Wakelee H; Ramalingam S; Belani CP
Expert Rev Anticancer Ther; 2005 Feb; 5(1):13-24. PubMed ID: 15757434
[TBL] [Abstract][Full Text] [Related]
37. Treatment of epidermal growth factor receptor inhibitor-induced severe paronychia with pyogenic granuloma-like lesions with topical betaxolol: an open-label observation study.
Yen CF; Hsu CK; Yang HS; Lee CN; Chi CC; Chung WH; Wang CL; Pang JS; Wang CW; Ko YS; Lu CW
Int J Dermatol; 2020 Mar; 59(3):326-332. PubMed ID: 31763692
[TBL] [Abstract][Full Text] [Related]
38. A cost-effectiveness analysis of docetaxel versus pemetrexed in second-line chemotherapy for stage IIIb or IV non-small cell lung cancer in China.
Yu YF; Chen ZW; Zhou Z; Song ZB; Li ZM; Jian H; Zhang YF; Lu S
Chemotherapy; 2010; 56(6):472-7. PubMed ID: 21099219
[TBL] [Abstract][Full Text] [Related]
39. Trastuzumab/docetaxel-induced nail dystrophy.
Alexandrescu DT; Vaillant J; Wiernik PH
Int J Dermatol; 2006 Nov; 45(11):1334-6. PubMed ID: 17076719
[No Abstract] [Full Text] [Related]
40. Periungual and subungual pyogenic granuloma.
Piraccini BM; Bellavista S; Misciali C; Tosti A; de Berker D; Richert B
Br J Dermatol; 2010 Nov; 163(5):941-53. PubMed ID: 20545691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
